Notably, estrogen receptor (ER)-negative breast cancers within the first 5 years post-diagnosis exhibit heightened susceptibility compared to their ER-positive counterparts, with risks persisting and escalating over a decade.[4] Human epidermal growth factor receptor 2 (HER2) status has emerged as a pivotal determinant. This evidence concerns the gene ERBB2 and breast carcinoma.